EEG coherence following acute and chronic clozapine in treatment-resistant schizophrenics

Experimental and Clinical Psychopharmacology

Volumn 10, Issue 4, 2002, Pages 435-444

  Knott, Verner J ^a   LaBelle, Alain ^a   Mahoney, Colleen ^a   Jones, Barry ^b  

^a ROYAL OTTAWA HOSPITAL   (Canada)

^b ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORPROMAZINE; CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ELECTROENCEPHALOGRAM; FEMALE; HUMAN; MALE; SCHIZOPHRENIA; SYMPTOM;

ADULT; ANTIPSYCHOTIC AGENTS; BRAIN MAPPING; CLOZAPINE; DELTA RHYTHM; DRUG ADMINISTRATION SCHEDULE; ELECTROENCEPHALOGRAPHY; FEMALE; HUMANS; MALE; MIDDLE AGED; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SEVERITY OF ILLNESS INDEX; SIGNAL PROCESSING, COMPUTER-ASSISTED; THETA RHYTHM; TIME FACTORS; TREATMENT OUTCOME;

EID: 0036857987     PISSN: 10641297     EISSN: None     Source Type: Journal    
DOI: 10.1037/1064-1297.10.4.435     Document Type: Article

References (78)

1. American Psychiatric Association. (1987). Diagnostic and Statistical Manual of Mental Disorders (3rd Ed., rev.). Washington, DC: Author.
2. Arnold, S. (1999). Cognition and neuropathology in schizophrenia. Acta Psychiatrica Scandinavica, 99, 41-50.
3. Bohrer, R., Cheung, M., Drasgow, F., McCabe, P., & Keren, G. (1980). New time-series statistics for detecting rhythmic cooccurrence in the frequency domain: The weighted coherence and its application to psychophysiological research. Psychological Bulletin, 88, 580-587.
4. Braff, D., & Swerdlow, N. (1997). Neuroanatomy of schizophrenia. Schizophrenia Bulletin, 23, 509-512.
5. Busk, J., & Gailbraith, G. (1975). EEG correlates of visual motor practice in man. Electroencephalography and Clinical Neurophysiology, 38, 415-422.
6. Callaway, E., & Harris, P. (1977). Coupling between cortical potentials from different areas. Science, 183, 873-875.
7. Coward, D. (1992). General pharmacology of clozapine. British Journal of Psychiatry, 160(Suppl. 17), 3-11.
8. Czobor, P., & Volavka, J. (1991). Pretreatment EEG predicts short-term response to haloperidol treatment. Biological Psychiatry, 30, 927-942.
9. Czobor, P., & Volavka, J. (1992). Level of haloperidol in plasma is related to electroencephalographic findings in patients who improve. Psychiatry Research, 42, 129-144.
10. Czobor, P., & Volavka, J. (1993). Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. Journal of Clinical Psychopharmacology, 13, 332-342.
11. DeBuck, R., Zelaschi, N., Gilles, C., Durdo, J., & Brauman, H. (1981). Theoretical and practical importance of plasma levels of haloperidol correlations with clinical and computerized EEG data. Progress in Neuro-Psychopharmacology, 5, 459-502.
12. Dolan, R., Fletcher, P., McKenna, P., Preston, K., & Frith, C. (1999). Abnormal neural integration related to cognition in schizophrenia. Acta Psychiatrica Scandinavica, 99, 58-67.
13. Essl, M., & Rappelsberger, R. (1998). EEG coherence and reference signals: Experimental results and mathematical explanations. Medical and Biological Engineering and Computing, 36, 399-406.
14. Fein, G., Raz, J., Brown, F., & Merrin, E. (1988). Common reference coherence data are confounded by power and phase effects. Electroencephalography and Clinical Neurophysiology, 69, 581-584.
15. Fitton, A., & Heel, R. (1990). Clozapine: A review of it's pharmacological properties and therapeutic use in schizophrenia. Drugs, 40, 722-747.
16. Flor-Henry, P., & Koles, Z. (1984). Statistical quantitative EEG studies of depression, mania, schizophrenia and normals. Biological Psychology, 19, 257-279.
17. Ford, M., Goethe, J., & Dekker, D. (1986). EEG coherence and power in the discrimination of psychiatric disorders and medication effects. Biological Psychiatry, 21, 1175-1188.
18. French, C., & Beaumont, J. (1984). A critical review of EEG coherence studies of hemisphere function. International Journal of Psychophysiology, 1, 241-254.
19. Friston, K. (1999). Schizophrenia and the disconnection hypothesis. Acta Psychiatrica Scandinavica, 99, 68-79.
20. Friston, K., & Frith, C. (1995). Schizophrenia: A disconnection syndrome? Clinical Neuroscience, 3, 89-97.
21. Fuster, J. (1999). Synopsis of function and dysfunction of the frontal lobe. Acta Psychiatrica Scandinavica, 99, 51-57.
22. Galderisi, S., Maj, M., Mucci, A., Bucci, P., & Kemali, D. (1994). QEEG alpha 1 changes after a single dose of high potency neuroleptics as a predictor of short-term response to treatment in schizophrenic patients. Biological Psychiatry, 353, 367-374.
23. Galhofer, B., Bauer, U., Lis, S., Krieger, S., & Gruppe, H. (1996). Cognitive dysfunction in schizophrenia: Comparison of treatment with atypical antipsychotic agents and conventional neuroleptic drugs. European Neuropsychopharmacology, 6, S2-13-S2-20.
24. Gevins, A., Doyle, J., Cutillo, B., Schaffer, R., Tannehill, R., Ghannam, J., et al. (1981). Electrical potentials in human brain during cognition: New method reveals dynamic patterns of correlation. Science, 213, 918-922.
25. Giannitrapani, D. (1980). The coherence of the EEG in normal and schizophrenic subjects. Electroencephalography and Clinical Neurophysiology, 49, 108.
26. Goldberg, T., Greenberg, R., Griffin, S., Gold, J., Kleinman, J., Pickar, D., et al. (1993). The effect of clozapine on cognition and psychiatric symptoms in patients with schizophrenia. British Journal of Psychiatry, 162, 43-48.
27. Goldman-Rakic, P., & Selemon, L. (1997). Functional and anatomical aspects of prefrontal pathology in schizophrenia. Schizophrenia Bulletin, 23, 437-458.
28. Haber, S., & Fudge, J. (1997). The interface between dopamine neurons and the amygdala: Implications for schizophrenia. Schizophrenia Bulletin, 23, 471-482.
29. Hagger, C., Buckley, P., Kenny, J., Friedman, L., Ubogy, D., & Meltzer, H. (1993). Improvement in cognitive function and psychiatric symptoms in schizophrenic patients receiving clozapine. Biological Psychiatry, 34, 702-712.
30. Herrmann, W. (1983). Electroencephalography in Drug Research. Stuttgart, Germany: Fischer.
31. Hoff, A., Faustman, W., Wieneke, M., Wreneke, M., Espinoza, S., Costa, M., et al. (1996). The effect of clozapine on symptom reduction, neurocognitive function and clinical management in treatment refractory state hospital schizophrenic inpatients. Neuropsychopharmacology, 15, 361-369.
32. Hoffman, R., Buchsbaum, M., Escobar, M., Makuch, R., Nuechterlein, R., & Guich, S. (1991). EEG coherence of prefrontal areas in normal and schizophrenic males during perceptual activation. Journal of Neuropsychiatry, 3, 169-175.
33. Itil, T. (1974). Psychotropic Drugs and the Human EEG. Basel, Switzerland: Karger.
34. Itil, T. (1977). Qualitative and quantitative EEG findings in schizophrenia. Schizophrenia Bulletin, 3, 61-79.
35. Itil, T., Marasa, J., Saletu, B., Davis, S., & Mucciard, A. (1975). Computerized EEG: Predictor of outcome in schizophrenia. Journal of Nervous and Mental Disease, 160, 183-253.
36. Itil, T., Saletu, B., Coffin, C., & Klingenberg, H. (1972). Quantitative EEG changes during thiothixene treatment of chronic schizophrenics. Clinical Electroencephalography, 3, 104-117.
37. Itil, T., Shapiro, D., Schneider, S., & Francis, J. (1981). Computerized EEG as a predictor of drug response in treatment resistant schizophrenics. Journal of Nervous and Mental Disease, 169, 629-637.
38. Jennings, J., & Wood, C. (1976). The E-adjustment procedure for repeated measures analyses of variance. Psychophysiology, 13, 277-278.
39. John, E., Prichep, P., & Easton, P. (1987). Normative data banks and neurometrics: Basic concepts, methods and results of norm constructions. In A. Gevins & A. Rémond (Eds.), Methods of Analyzing Bioelectric and Magnetic Signals: EEG Handbook of Electroencephalography and Clinical Neurophysiology, Revised Series (Vol. 2, pp. 449-495). New York: Elsevier Science.
40. Kane, J., & Freeman, H. (1994). Towards more effective antipsychotic treatment. British Journal of Psychiatry, 165(Suppl. 25), 22-31.
41. Kane, J., Honigfeld, G., Singer, J., Meltzer, H., & the Clozaril Collaborative Study Group. (1988). Clozapine for the treatment-resistant schizophrenic: A double-blind comparison with chlorpromazine. Archives of General Psychiatry, 45, 789-796.
42. Kay, S., Opler, L., & Lindenmayer, J. (1988). Reliability and validity of the positive and negative syndrome scale in schizophrenia. Psychiatry Research, 23, 99-110.
43. Kay, S., Opler, L., & Lindenmayer, J. (1989). The Positive and Negative Scale (PANSS): Rationale and standardization. British Journal of Psychiatry, 155, 59-65.
44. Kerwin, R. (1994). The new atypical antipsychotics: A lack of extrapyramidal side effects and new routes in schizophrenia research. British Journal of Psychiatry, 164, 141-148.
45. Klimesch, W., Doppelmayr, M., Schwaiger, J., Winkler, T., & Gruber, W. (2000). Theta oscillations and the ERP old/new effect: Independent phenomena? Clinical Neurophysiology, 111, 781-793.
46. Klimesch, W., Schimke, H., & Schwaiger, J. (1994). Episodic semantic memory: An analysis in the EEG theta and alpha band. Electroencephalography and Clinical Neurophysiology, 91, 428-441.
47. Knott, V. (2000). Quantitative EEG methods and measures in human psychopharmacological research. Human Psychopharmacology, 15, 479-498.
48. Mann, K., Maier, W., Franke, P., Roeschke, J., & Gaensicke, M. (1997). Intra- and interhemispheric electroencephalogram coherence in siblings discordant for schizophrenia and healthy volunteers. Biological Psychiatry, 42, 655-663.
49. Manschreck, T., Redmond, D., Candela, S., & Maher, B. (1999). Effects of clozapine on psychiatric symptoms, cognition and functional outcome in schizophrenia. Journal of Neuropsychiatry and Clinical Neuroscience, 11, 481-489.
50. May, P., Itil, T., Van Patten, T., Lee, M., & Yale, C. (1982). A preliminary attempt to relate individual differences in EEG test dose response to clinical effect. Biological Psychiatry, 17, 599-603.
51. McGlashan, T., & Hoffman, R. (2000). Schizophrenia as a disorder of developmentally reduced synaptic connectivity. Archives of General Psychiatry, 57, 637-648.
52. Merrin, E., & Floyd, T. (1992). Negative symptoms and EEG alpha activity in schizophrenic patients. Schizophrenia Research, 8, 11-20.
53. Merrin, E., & Floyd, T. (1996). Negative symptoms and EEG alpha in schizophrenia: A replication. Schizophrenia Research, 19, 151-161.
54. Merrin, E., Floyd, T., & Fein, G. (1989). EEG coherence in unmedicated schizophrenic patients. Biological Psychiatry, 25, 60-66.
55. Nagase, Y., Okubo, Y., Matsuura, M., Kojima, T., & Toru, M. (1992). EEG coherence in unmedicated schizophrenic patients: Topographical study of predominantly never medicated cases. Biological Psychiatry, 32, 1028-1034.
56. Newton, T., Leuchtor, A., Walter, D., Van Garp, W., Stern, C., Mandelkern, M., & Weines, H. (1993). EEG coherence in men with AIDS: Association with subcortical metabolic activity. Journal of Neuropsychiatry, 5, 316-321.
57. Nunez, P. (1981). Electrical Fields of the Brain: The Neurophysics of EEG. New York: Oxford University Press.
58. Nunez, P., Silberstein, R., Shi, Z., Carpenter, M., Srinivasan, R., Tucker, D., et al. (1999). EEG coherency II: Experimental comparisons of multiple measures. Clinical Neurophysiology, 110, 469-486.
59. Nunez, P., Srinivasan, R., Westdorp, A., Wijesinghe, R., Tucker, D., Silberstein, R., & Cadusch, P. (1997). EEG coherency. I: Statistics, reference electrode, volume conduction, Laplacians cortical imaging and interpretation at multiple scales. Electroencephalography and Clinical Neurophysiology, 103, 499-515.
60. Pockberger, H., Thau, K., Lovrek, A., Petsche, H., & Rappelsberger, P. (1989). Coherence mapping reveals differences in the EEG between psychiatric patients and healthy persons. In K. Maurer (Ed.), Topographic Brain Mapping of EEG and Evoked Potentials (pp. 451-457). Berlin, Germany: Springer-Verlag.
61. Prichep, L., & John, E. (1992). QEEG profiles of psychiatric disorders. Brain Topography, 4, 249-257.
62. Purdon, S. (1999). Cognitive improvement in schizophrenia with novel antipsychotic medications. Schizophrenia Research, 35, S51-S60.
63. Rappelsberger, P., & Petsche, H. (1988). Probability mapping: Power and coherence analyses of cognitive processes. Brain Topography, 1, 46-53.
64. Risch, S. (1996). Pathophysiology of schizophrenia and the role of newer antipsychotics. Pharmacotherapy, 16, 11-14.
65. Rosenheck, R., Evans, D., Herz, L., Cramer, T., Xu, W., Thomas, J., et al. (1999). Schizophrenia Bulletin, 25, 709-719.
66. Saletu, B. (1987). The use of pharmaco-EEG in drug profiling, In I. Hindmarch & P. Stonier (Eds.), Human Psychopharmacology in Measures and Methods. (pp. 173-200). Chichester, England: Wiley.
67. Shaw, J., Brooks, S., Colter, N., & O'Connor, K. (1979). A comparison of schizophrenic and neurotic patients using EEG power and coherence spectra. In J. Gruzelier & P. Flor-Henry (Eds.), Hemisphere Asymmetries of Function in Psychopathology (pp. 257-292). Amsterdam: Elsevier/North Holland Biomedical Press.
68. Shaw, J., Colter, N., & Resek, G. (1983). EEG coherence, lateral preference and schizophrenia. Psychological Medicine, 13, 299-306.
69. Small, J., Milstein, V., Small, I., Miller, M., Kellams, J., & Corsaro, C. (1987). Computerized EEG profiles of haloperidol, chlorpromazine, clozapine and placebo in treatment resistant schizophrenia. Clinical Electroencephalography, 18, 124-136.
70. Tauscher, J., Fischer, P., Neumeister, A., Rappelsberger, R., & Kasper, S. (1998). Low frontal electroencephalographic coherence in neuroleptic-free schizophrenic patients. Biological Psychiatry, 44, 438-447.
71. Thatcher, R., Krause, P., & Hrybyk, M. (1986). Cortico-cortical associations and EEG coherence: A two-compartmental model. Electroencephalography and Clinical Neurophysiology, 64, 123-143.
72. Tihonen, J., Nousiainen, V., Hakola, P., Leinonen, E., Tuunainen, A., Mervaala, E., & Puanila, J. (1993). EEG abnormalities associated with clozapine treatment. American Journal of Psychiatry, 148, 1406.
73. Tucker, D., Roth, D., & Blair, T. (1986). Functional connections among cortical regions: Topography of EEG coherence. Electrocencephalography and Clinical Neurophysiology, 63, 242- 250.
74. Wada, Y., Nanbu, Y., Jiang, Z., Koshino, Y., & Hashimoto, T. (1998). Interhemispheric EEG in never-medicated patients with paranoid schizophrenia: Analysis at rest and during photic stimulation. Clinical Electroencephalography, 29, 170-176.
75. Wada, Y., Nanbu, Y., Kikuchi, M., Koshino, Y., & Hashimoto, T. (1998). Aberrant functional organization in schizophrenia: Analysis of EEG coherence during rest and photic stimulation in drug-naive patients. Neuropsychobiology, 38, 63-64.
76. Walker, E., & Levine, R. (1988). The positive/negative symptom distinction in schizophrenia: Validity and etiological relevance. Schizophrenia Research, 1, 315-328.
77. Weller, M., & Montagu, J. (1980). Electroencephalographic coherence in schizophrenia: A preliminary study. Electroencephalography and Clinical Neurophysiology, 49, 100.
78. Zihl, J., Von Cramon, D., & Mai, N. (1983). Selective disturbance of movement vision after bilateral brain damage. Brain, 106, 313-340.